| 000 | 01689 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250513084251.0 | ||
| 264 | 0 | _c19960227 | |
| 008 | 199602s 0 0 eng d | ||
| 022 | _a0959-8138 | ||
| 024 | 7 |
_a10.1136/bmj.311.7020.1602 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLees, A J | |
| 245 | 0 | 0 |
_aComparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. _h[electronic resource] |
| 260 |
_bBMJ (Clinical research ed.) _cDec 1995 |
||
| 300 |
_a1602-7 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntiparkinson Agents _xadverse effects |
| 650 | 0 | 4 |
_aBenserazide _xadministration & dosage |
| 650 | 0 | 4 |
_aBromocriptine _xadministration & dosage |
| 650 | 0 | 4 | _aCause of Death |
| 650 | 0 | 4 | _aDisability Evaluation |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLevodopa _xadministration & dosage |
| 650 | 0 | 4 |
_aMonoamine Oxidase Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aSelegiline _xadministration & dosage |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Failure |
| 773 | 0 |
_tBMJ (Clinical research ed.) _gvol. 311 _gno. 7020 _gp. 1602-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1136/bmj.311.7020.1602 _zAvailable from publisher's website |
| 999 |
_c8554877 _d8554877 |
||